Details for Patent: 10,342,780

Which drugs does patent 10,342,780 protect, and when does it expire?

Patent 10,342,780 protects JAYPIRCA and is included in one NDA.

This patent has seventy patent family members in thirty-five countries.

Summary for Patent: 10,342,780

Title:	Compounds useful as kinase inhibitors
Abstract:	This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
Inventor(s):	Guisot Nicolas
Assignee:	Loxo Oncology, Inc.
Application Number:	US16109162
Patent Claim Types: see list of patent claims

Drugs Protected by US Patent 10,342,780

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Loxo Oncol	JAYPIRCA	pirtobrutinib	TABLET;ORAL	216059-001	Jan 27, 2023		RX	Yes	No			Y	Y
Loxo Oncol	JAYPIRCA	pirtobrutinib	TABLET;ORAL	216059-002	Jan 27, 2023		RX	Yes	Yes			Y	Y

International Family Members for US Patent 10,342,780

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2016373530
Australia	2021201811
Australia	2021225161
Australia	2021225162
Brazil	112018012341